Subtype
High Grade Astrocytic Tumor
CI-CAN-00005503Explore in graph →
495 active trials2 approved drugs51 evidence items
- NCIt
- C102897
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005503Explore in graph →
Clinical trials
1,778 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (282)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02698280 | Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma | completed | Phase 2 | 23 | Huashan HospitalOTHER | 1 | Jul 31, 2018 | clinicaltrials |
| NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | unknown | Phase 1 / Phase 2 | 160 | Leaf Vertical Inc.INDUSTRY | 1 | Jul 31, 2018 | clinicaltrials |
| Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma |
| completed |
| Phase 2 |
| 17 |
| Dana-Farber Cancer InstituteOTHER |
| 1 |
| Jul 24, 2018 |
| clinicaltrials |
| NCT01836549 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | terminated | Phase 2 | 43 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jul 20, 2018 | clinicaltrials |
| NCT01907165 | Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide | completed | Early Phase 1 | 21 | Washington University School of MedicineOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT02540135 | Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma | withdrawn | N/A | 0 | University of Colorado, DenverOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT03275558 | Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma | withdrawn | Phase 1 | 0 | Center Trials & TreatmentOTHER | 2 | Jul 19, 2018 | clinicaltrials |
| NCT00919750 | Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors | completed | — | 1,258 | Children's Oncology GroupNETWORK | 6 | Jul 16, 2018 | clinicaltrials |
| NCT00107003 | GW572016 to Treat Recurrent Malignant Brain Tumors | completed | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01281982 | (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas | terminated | — | 2 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01086345 | Radiosurgery Plus Bevacizumab in Glioblastoma | terminated | Early Phase 1 | 9 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT01234805 | Yoga Therapy in Treating Patients With Malignant Brain Tumors | terminated | N/A | 9 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT00335764 | Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01644955 | Carboplatin in Treating Patients With Recurrent High-Grade Gliomas | completed | Phase 1 | 10 | James ElderOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02345824 | Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma | unknown | Phase 1 | 3 | University of VirginiaOTHER | 1 | Jun 7, 2018 | clinicaltrials |
| NCT01091792 | Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM) | completed | Early Phase 1 | 13 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | May 25, 2018 | clinicaltrials |
| NCT01648348 | Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 116 | National Cancer Institute (NCI)NIH | 1 | May 23, 2018 | clinicaltrials |
| NCT01156584 | A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma | completed | Phase 1 | 54 | Tocagen Inc.INDUSTRY | 1 | May 21, 2018 | clinicaltrials |
| NCT01470794 | Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor | completed | Phase 1 | 58 | Tocagen Inc.INDUSTRY | 1 | May 21, 2018 | clinicaltrials |
| NCT01985256 | Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor | completed | Phase 1 | 17 | Tocagen Inc.INDUSTRY | 1 | May 21, 2018 | clinicaltrials |
| NCT02157103 | A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma | completed | Phase 2 | 3 | Emory UniversityOTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT01124461 | BIRN (Biomedical Informatics Research Network) Resources Facilitate the Personalization of Malignant Brain Tumor(CONDR) | completed | — | 112 | Washington University School of MedicineOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT01602588 | A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)(HCQ) | completed | Phase 2 | 54 | University College, LondonOTHER | 1 | May 3, 2018 | clinicaltrials |
| NCT00990496 | A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM) | terminated | Phase 1 | 25 | Milton S. Hershey Medical CenterOTHER | 0 | May 2, 2018 | clinicaltrials |
| NCT01860638 | A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma | completed | Phase 2 | 296 | Hoffmann-La RocheINDUSTRY | 15 | Apr 30, 2018 | clinicaltrials |
| NCT02227576 | Prevention of Thrombocytopenia in Glioblastoma Patients(PLATUM) | terminated | Phase 2 | 20 | University Hospital, LilleOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT02466828 | qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia. | completed | Early Phase 1 | 10 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01234740 | Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases | completed | Phase 1 | 7 | City of Hope Medical CenterOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT02945826 | uPAR-PET/MRI in Glioblastoma Multiforme | unknown | Phase 2 | 35 | Rigshospitalet, DenmarkOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT01702792 | Derivation of Tumor Specific Hybridomas | terminated | Phase 1 | 1 | Dartmouth-Hitchcock Medical CenterOTHER | 0 | Apr 4, 2018 | clinicaltrials |
| NCT02507102 | A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM) in Australia | completed | N/A | 11 | Nativis, Inc.INDUSTRY | 1 | Mar 30, 2018 | clinicaltrials |
| NCT00003456 | Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme | completed | Phase 2 | 40 | Burzynski Research InstituteOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT00003474 | Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme | completed | Phase 2 | 40 | Burzynski Research InstituteOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT02654041 | Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients | terminated | Phase 2 | 3 | Musli Thyropeutics Ltd.INDUSTRY | 1 | Mar 22, 2018 | clinicaltrials |
| NCT00200161 | Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma | completed | Phase 2 | 127 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 7, 2018 | clinicaltrials |
| NCT00305864 | Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 118 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2018 | clinicaltrials |
| NCT01618747 | An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Relapse | completed | — | 20 | Hoffmann-La RocheINDUSTRY | 1 | Feb 28, 2018 | clinicaltrials |
| NCT02254954 | Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma | terminated | Phase 1 | 30 | ActelionINDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT01765088 | A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas | unknown | Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT02629757 | A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas(β-elemene) | unknown | Phase 3 | 100 | Sun Yat-sen UniversityOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT01788280 | Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab | withdrawn | Phase 2 | 0 | University of UtahOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT01632228 | A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma | completed | Phase 2 | 135 | Hoffmann-La RocheINDUSTRY | 8 | Feb 5, 2018 | clinicaltrials |
| NCT02047214 | Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy | terminated | Phase 2 | 17 | Cortice Biosciences, Inc.INDUSTRY | 1 | Jan 31, 2018 | clinicaltrials |
| NCT02590497 | Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | Jan 31, 2018 | clinicaltrials |
| NCT00693095 | Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer(ERaDICATe) | completed | Phase 1 | 23 | John SampsonOTHER | 1 | Jan 30, 2018 | clinicaltrials |
| NCT01342757 | Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma | completed | N/A | 12 | National Cancer Institute (NCI)NIH | 1 | Jan 29, 2018 | clinicaltrials |
| NCT01782976 | Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 19, 2018 | clinicaltrials |
| NCT02910804 | IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Glioblastoma | unknown | Early Phase 1 | 30 | Beijing Tiantan HospitalOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT03401866 | Multi-site Validation and Application of a Consensus DSC-MRI Protocol | unknown | N/A | 80 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Jan 17, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jul 31, 2018source: clinicaltrials